[go: up one dir, main page]

DE69625691D1 - Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten - Google Patents

Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten

Info

Publication number
DE69625691D1
DE69625691D1 DE69625691T DE69625691T DE69625691D1 DE 69625691 D1 DE69625691 D1 DE 69625691D1 DE 69625691 T DE69625691 T DE 69625691T DE 69625691 T DE69625691 T DE 69625691T DE 69625691 D1 DE69625691 D1 DE 69625691D1
Authority
DE
Germany
Prior art keywords
treatment
peptidylheterocycles
thrombine
administration
related diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69625691T
Other languages
English (en)
Other versions
DE69625691T2 (de
Inventor
J Costanzo
E Maryanoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Ortho Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Pharmaceutical Corp filed Critical Ortho Pharmaceutical Corp
Publication of DE69625691D1 publication Critical patent/DE69625691D1/de
Application granted granted Critical
Publication of DE69625691T2 publication Critical patent/DE69625691T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • C07K5/0222—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE69625691T 1995-06-07 1996-06-03 Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten Expired - Fee Related DE69625691T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/486,473 US5523308A (en) 1995-06-07 1995-06-07 Peptidyl heterocycles useful in the treatment of thrombin related disorders
PCT/US1996/008456 WO1996040748A1 (en) 1995-06-07 1996-06-03 Peptidyl heterocycles useful in the treatment of thrombin related disorders

Publications (2)

Publication Number Publication Date
DE69625691D1 true DE69625691D1 (de) 2003-02-13
DE69625691T2 DE69625691T2 (de) 2003-10-23

Family

ID=23932026

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69625691T Expired - Fee Related DE69625691T2 (de) 1995-06-07 1996-06-03 Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten

Country Status (21)

Country Link
US (1) US5523308A (de)
EP (1) EP0833839B1 (de)
JP (1) JPH11506762A (de)
KR (1) KR100434667B1 (de)
CN (1) CN1146575C (de)
AT (1) ATE230757T1 (de)
AU (1) AU721079B2 (de)
CA (1) CA2224110A1 (de)
CZ (1) CZ386997A3 (de)
DE (1) DE69625691T2 (de)
DK (1) DK0833839T3 (de)
ES (1) ES2191102T3 (de)
IL (1) IL122436A (de)
MX (1) MX9709915A (de)
NO (1) NO975747L (de)
NZ (1) NZ309523A (de)
PL (1) PL184986B1 (de)
RU (1) RU2181125C2 (de)
TW (1) TW470751B (de)
WO (1) WO1996040748A1 (de)
ZA (1) ZA964759B (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857633A (en) * 1984-06-25 1989-08-15 Exxon Research & Engineering Company Method for high temperature phase separation of solutions containing polymers
US5827860A (en) * 1995-06-07 1998-10-27 Ortho Pharmaceutical Corporation Peptidyl heterocycles useful in the treatment of thrombin related disorders
US5721214A (en) * 1995-06-07 1998-02-24 Cor Therapeutics, Inc. Inhibitors of factor Xa
US6211154B1 (en) 1995-06-07 2001-04-03 Cor Therapeutics, Inc. Ketoheterocyclic inhibitors of factor Xa
US6069130A (en) 1995-06-07 2000-05-30 Cor Therapeutics, Inc. Ketoheterocyclic inhibitors of factor Xa
US6022861A (en) * 1995-06-07 2000-02-08 Cor Therapeutics, Inc. Ketoheterocyclic inhibitors of factor Xa
US5827866A (en) * 1995-06-07 1998-10-27 Ortho Pharmaceutical Corporation Peptidyl heterocycles useful in the treatment of thrombin related disorders
US5919765A (en) * 1995-06-07 1999-07-06 Cor Therapeutics, Inc. Inhibitors of factor XA
US6046169A (en) * 1995-06-07 2000-04-04 Cor Therapeutics, Inc. Inhibitors of factor XA
IL119466A (en) * 1995-11-03 2001-08-26 Akzo Nobel Nv Thrombin inhibitors, their preparation and pharmaceutical compositions containing them
US5811402A (en) * 1996-03-22 1998-09-22 Eli Lilly And Company Antithrombotic diamides
US6245743B1 (en) 1996-06-05 2001-06-12 Cor Therapeutics, Inc. Inhibitors of factor Xa
US6063794A (en) * 1996-10-11 2000-05-16 Cor Therapeutics Inc. Selective factor Xa inhibitors
JP2001502674A (ja) * 1996-10-11 2001-02-27 シーオーアール・セラピューティックス・インコーポレーテッド 選択的Ｘａ因子阻害物質
US6369080B2 (en) 1996-10-11 2002-04-09 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6194435B1 (en) * 1996-10-11 2001-02-27 Cor Therapeutics, Inc. Lactams as selective factor Xa inhibitors
US6262047B1 (en) 1996-10-11 2001-07-17 Cor Therapeutics, Inc. Selective factor Xa inhibitors
WO1998016524A1 (en) * 1996-10-11 1998-04-23 Cor Therapeutics, Inc. HETEROCYCLIC DERIVATIVES AS FACTOR Xa INHIBITORS
EP0932615A1 (de) * 1996-10-11 1999-08-04 Cor Therapeutics, Inc. SELEKTIVE FACTOR Xa INHIBITOREN
CA2285705A1 (en) * 1997-04-14 1998-10-22 Cor Therapeutics, Inc. Selective factor xa inhibitors
CA2285659A1 (en) 1997-04-14 1998-10-22 Cor Therapeutics, Inc. Selective factor xa inhibitors
WO1998046626A1 (en) 1997-04-14 1998-10-22 Cor Therapeutics, Inc. SELECTIVE FACTOR Xa INHIBITORS
EP0884325A1 (de) * 1997-04-24 1998-12-16 Akzo Nobel N.V. Inhibitoren des Thrombins, die einen peptid-Heterocyclus aufweisen
US5877156A (en) * 1997-04-24 1999-03-02 Akzo Nobel, N.V. Thrombin inhibitors
WO1998051684A1 (en) * 1997-05-15 1998-11-19 Eli Lilly And Company Antithrombotic compound
US8039026B1 (en) * 1997-07-28 2011-10-18 Johnson & Johnson Consumer Companies, Inc Methods for treating skin pigmentation
AU2006252275A1 (en) * 1997-07-28 2007-01-25 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin pigmentation
US6218382B1 (en) 1997-08-11 2001-04-17 Cor Therapeutics, Inc Selective factor Xa inhibitors
US6333321B1 (en) 1997-08-11 2001-12-25 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6228854B1 (en) 1997-08-11 2001-05-08 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6323219B1 (en) 1998-04-02 2001-11-27 Ortho-Mcneil Pharmaceutical, Inc. Methods for treating immunomediated inflammatory disorders
US8106094B2 (en) 1998-07-06 2012-01-31 Johnson & Johnson Consumer Companies, Inc. Compositions and methods for treating skin conditions
US6750229B2 (en) 1998-07-06 2004-06-15 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin pigmentation
US8093293B2 (en) * 1998-07-06 2012-01-10 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin conditions
EA200100815A1 (ru) * 1999-01-27 2002-08-29 Орто-Макнейл Фармасьютикал, Инк. Пептидильные гетероциклические кетоны, применимые в качестве ингибиторов триптазы
US7985404B1 (en) 1999-07-27 2011-07-26 Johnson & Johnson Consumer Companies, Inc. Reducing hair growth, hair follicle and hair shaft size and hair pigmentation
US7309688B2 (en) 2000-10-27 2007-12-18 Johnson & Johnson Consumer Companies Topical anti-cancer compositions and methods of use thereof
GB0004686D0 (en) * 2000-02-28 2000-04-19 Aventis Pharma Ltd Chemical compounds
SI20582A (sl) * 2000-05-05 2001-12-31 Univerza V Ljubljani Novi inhibitorji trombina, njihova priprava in uporaba
US6960597B2 (en) * 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
DE10046934A1 (de) * 2000-09-21 2002-04-18 Consortium Elektrochem Ind Verfahren zur fermentativen Herstellung von nicht-proteinogenen L-Aminosäuren
US8431550B2 (en) 2000-10-27 2013-04-30 Johnson & Johnson Consumer Companies, Inc. Topical anti-cancer compositions and methods of use thereof
US7192615B2 (en) 2001-02-28 2007-03-20 J&J Consumer Companies, Inc. Compositions containing legume products
US6555143B2 (en) 2001-02-28 2003-04-29 Johnson & Johnson Consumer Products, Inc. Legume products
KR20030080810A (ko) * 2002-04-11 2003-10-17 주식회사 엘지생명과학 아미노피리도아릴 그룹을 가진 선택적 트롬빈 억제제
US7091360B2 (en) * 2002-04-16 2006-08-15 Aventis Pharma S.A. Process for preparing heteroaryl and unsaturated heterocycloalkylmagnesium reagents and uses thereof
US7375093B2 (en) * 2002-07-05 2008-05-20 Intrexon Corporation Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US20040063593A1 (en) * 2002-09-30 2004-04-01 Wu Jeffrey M. Compositions containing a cosmetically active organic acid and a legume product
US7393920B2 (en) 2003-06-23 2008-07-01 Cem Corporation Microwave-assisted peptide synthesis
US20050176755A1 (en) * 2003-10-31 2005-08-11 Dyatkin Alexey B. Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists
ATE371649T1 (de) * 2004-02-10 2007-09-15 Janssen Pharmaceutica Nv Pyridazinonharnstoffe als antagonisten von a4- integrinen
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
RU2419625C2 (ru) * 2006-05-23 2011-05-27 Айрм Ллк Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы
EP2027143A2 (de) * 2006-05-23 2009-02-25 Irm Llc Verbindungen und zusammensetzungen als kanalaktivierende protease-hemmer
TWI389899B (zh) * 2006-08-08 2013-03-21 Msd Oss Bv 具口服活性之凝血酶抑制劑
BRPI0806970A2 (pt) * 2007-02-09 2014-04-08 Irm Llc Compostos e composições como inibidores de protease de ativação de canal
WO2008097676A1 (en) * 2007-02-09 2008-08-14 Irm Llc Compounds and compositions as channel activating protease inhibitors
EP2714716B1 (de) 2011-06-02 2018-04-11 Socpra Sciences Santé Et Humaines S.E.C. Matriptase-hemmer und verwendungen davon gegen orthomyxoviridae-infektionen
CN104003984B (zh) * 2014-06-16 2016-03-02 山东大学 噻唑-4-甲酰基哌嗪衍生物及其制备方法与应用
US9758473B2 (en) * 2014-10-06 2017-09-12 Cortexyme, Inc. Inhibitors of lysine gingipain
WO2017083433A1 (en) * 2015-11-09 2017-05-18 Cortexyme, Inc. Inhibitors of arginine gingipain
EP4480541A3 (de) 2016-09-16 2025-04-30 Lighthouse Pharmaceuticals, Inc. Ketonhemmer von lysin-gudipain
US11352394B2 (en) 2016-11-22 2022-06-07 Ohio State Innovation Foundation Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof
US20190309020A1 (en) * 2016-11-22 2019-10-10 Ohio State Innovation Foundation Cell-penetrating peptide sequences
WO2019070962A1 (en) 2017-10-04 2019-04-11 Ohio State Innovation Foundation BICYCLIC PEPTIDE INHIBITORS
EP3746105A4 (de) 2018-01-29 2022-05-18 Ohio State Innovation Foundation Zyklische peptidylinhibitoren der cal-pdz-bindenden domäne
US11987647B2 (en) 2018-05-09 2024-05-21 Ohio State Innovation Foundation Cyclic cell-penetrating peptides with one or more hydrophobic residues
EP3817776A4 (de) 2018-07-02 2022-11-30 Ohio State Innovation Foundation Polypeptidkonjugate zur intrazellulären freisetzung von nukleinsäuren
CN117143179B (zh) * 2023-09-18 2024-07-12 安徽峆一药业股份有限公司 一种凝血酶发色底物s-2238的合成方法
CN118754827B (zh) * 2024-06-27 2025-03-25 成都普康唯新生物科技有限公司 含保护基的α-甲基鸟氨酸的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5332726A (en) * 1989-09-29 1994-07-26 Rhone-Poulenc Rorer Pharmaceuticals Inc. Antithrombotic peptides and pseudopeptides
EP0503203A1 (de) * 1991-03-15 1992-09-16 Merrell Dow Pharmaceuticals Inc. Neue Thrombin-Inhibitoren
PT626968E (pt) * 1992-02-13 2002-03-28 Merrell Pharma Inc Derivados de piperidinilo tiaciclicos
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
EP0648780A1 (de) * 1993-08-26 1995-04-19 Bristol-Myers Squibb Company Heterozyklische Thrombinhemmer
JPH0820597A (ja) * 1994-07-07 1996-01-23 Meiji Seika Kaisha Ltd トロンビン阻害作用を有する複素環カルボニル化合物

Also Published As

Publication number Publication date
RU2181125C2 (ru) 2002-04-10
ES2191102T3 (es) 2003-09-01
EP0833839A1 (de) 1998-04-08
CN1192747A (zh) 1998-09-09
CZ386997A3 (cs) 1998-07-15
US5523308A (en) 1996-06-04
MX9709915A (es) 1998-08-30
AU5971396A (en) 1996-12-30
NO975747L (no) 1998-02-03
ATE230757T1 (de) 2003-01-15
CN1146575C (zh) 2004-04-21
IL122436A (en) 2004-06-20
NO975747D0 (no) 1997-12-05
PL323825A1 (en) 1998-04-27
EP0833839B1 (de) 2003-01-08
PL184986B1 (pl) 2003-01-31
ZA964759B (en) 1997-12-08
NZ309523A (en) 1999-11-29
KR19990022568A (ko) 1999-03-25
CA2224110A1 (en) 1996-12-19
WO1996040748A1 (en) 1996-12-19
DE69625691T2 (de) 2003-10-23
JPH11506762A (ja) 1999-06-15
KR100434667B1 (ko) 2004-09-24
TW470751B (en) 2002-01-01
DK0833839T3 (da) 2003-04-14
AU721079B2 (en) 2000-06-22

Similar Documents

Publication Publication Date Title
DE69625691D1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
DE59409312D1 (de) Imidazopyridine und ihre anwendung zur behandlung von magen-darm krankheiten
ATE207349T1 (de) Thip zur behandlung von schlafstörungen
DE69736441D1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
DE60236413D1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
DE69507029D1 (de) Pharmazeutische zusammensetzungen enthaltend einen opiat antagonist und calcium salze, ihre verwendung zur behandlung von endorphin-vermittelten krankheiten
DE69733132D1 (de) Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen
DE69822665D1 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
DE69412552D1 (de) Medizinisches Instrument zur Behandlung von Sinusitis
DE69626539D1 (de) topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen
ATE202706T1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
DE69509544D1 (de) Zusammensetzung zur behandlung ovarieller östrogenabhängiger krankheiten
DE69427344D1 (de) Verabreichung von riluzol zur behandlung von neuro-aids
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
ATE201992T1 (de) Carbostyrilderivat zur behandlung von ophthalmologischen erkrankungen
DE69927147D1 (de) Verwendung von osteoprotegerin zur vorbeugung und behandlung cardiovaskulärer erkrankungen
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
DE69420229D1 (de) Pharmazeutische Zusammensetzung zur Behandlung von AIDS
DE69805305D1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE223721T1 (de) Edelfosin zur behandlung von hirntumoren
TR200200278T2 (tr) Kalsilitik bileşimler
DE69739190D1 (de) Arzneimittel zur behandlung von oculären kreislauferkrankungen
ATE293994T1 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen
ATE249837T1 (de) Caspase 8-inhibitoren zur immunsuppression
ATE203671T1 (de) Imidazolochinoxalinone zur behandlung zentralnervöser erkrankungen

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: ORTHO-MCNEIL PHARMACEUTICAL, INC., RARITAN, N.J.,

8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: BOEHMERT & BOEHMERT, 28209 BREMEN

8339 Ceased/non-payment of the annual fee